Nevro Corp. closes $58 million financing round to fund U.S. pivotal trial of spinal cord stimulation system for pain management.

Nevro Corp., an early stage company that makes a spinal cord stimulator for chronic pain, has raised $58 million to continue development of its flagship product and prepare for a possible U.S. launch.
The Menlo Park, Calif.-based company said the funding round was led by Johnson & Johnson Development Corp. (NYSE: JNJ), along with existing investors Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners.
U.K. researchers report that Medtronic's CoreValve transcatheter aortic valve implantation system is...
Covidien champions positive results for the Barrett's esophagus ablation device it acquired along...
Illinois healthcare giant Abbott lands European regulatory approval for the Xience Xpedition 48,...
ALung Technologies says it's going for a Chinese regulatory nod for its Hemolung respiratory assist...
An attorney for a plaintiff suing robot-assisted surgical systems maker Intuitive Surgical says the...